|
| 38035554 | Untangling Complexities of Acute Myeloid Leukemia Review Series. | Acta Haematol | 2024 |
| 38052038 | Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. | Blood Adv | 2024 |
| 37935977 | A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. | Leukemia | 2024 |
| 37683132 | Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. | JCO Oncol Pract | 2024 |
| 36117402 | Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. | J Med Virol | 2023 |
| 37483562 | Prediction of risk for myeloid malignancy in clonal hematopoiesis. | NEJM Evid | 2023 |
| 38060271 | FLT(3)-ing about: the search for the best inhibitor. | Blood | 2023 |
| 37652597 | All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results. | Lancet Haematol | 2023 |
| 37693068 | Quatramer⿢ encapsulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer. | Bioeng Transl Med | 2023 |
| 37354069 | Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. | Am J Hematol | 2023 |
| 37058684 | Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. | JCO Oncol Pract | 2023 |
| 37156478 | Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37451200 | Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. | Leuk Res | 2023 |
| 37432068 | Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. | Blood Adv | 2023 |
| 37329769 | Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. | J Geriatr Oncol | 2023 |
| 37196637 | Association of social deprivation with survival in younger adult patients with AML: an Alliance study. | Blood Adv | 2023 |
| 37163357 | FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged â¿¥60 years. | Blood Adv | 2023 |
| 37195769 | Updates in Risk Stratification in Myelodysplastic Syndromes. | Cancer J | 2023 |
| 36922593 | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. | Nature | 2023 |
| 36922589 | MEN1 mutations mediate clinical resistance to menin inhibition. | Nature | 2023 |
| 36655338 | Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial. | Cancer | 2023 |
| 36780343 | Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia. | Blood Adv | 2023 |
| 36581735 | An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. | Nat Cancer | 2023 |
| 36399715 | North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. | Blood | 2023 |
| 36877915 | The International Consensus Classification of acute leukemias of ambiguous lineage. | Blood | 2023 |
| 36805300 | Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. | Blood Rev | 2023 |
| 36577290 | Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. | Leuk Res | 2023 |
| 36508268 | Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. | Blood Adv | 2023 |
| 36534523 | Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. | Clin Cancer Res | 2023 |
| 36658429 | Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. | Nat Cancer | 2023 |
| 36594187 | Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. | Am J Hematol | 2023 |
| 36332187 | Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. | Blood | 2023 |
| 36269846 | The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. | Blood Adv | 2023 |
| 36264143 | A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. | Cancer Discov | 2023 |
| 36322825 | Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. | Blood Adv | 2023 |
| 36287540 | Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. | Leuk Lymphoma | 2023 |
| 34261293 | Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. | Haematologica | 2022 |
| 35349669 | Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. | Blood Adv | 2022 |
| 35767897 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. | Blood | 2022 |
| 35792553 | Controlled variable selection in Weibull mixture cure models for high-dimensional data. | Stat Med | 2022 |
| 35696629 | Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. | J Clin Oncol | 2022 |
| 35427411 | Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. | Blood | 2022 |
| 35853853 | BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. | Blood Cancer J | 2022 |
| 35788257 | High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. | Blood Adv | 2022 |
| 35486475 | Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. | Blood Adv | 2022 |
| 35714308 | TET2-mutant clonal hematopoiesis and risk of gout. | Blood | 2022 |
| 36517130 | Consolidation chemotherapy in AML: Are we playing with a full deck of cards? | Best Pract Res Clin Haematol | 2022 |
| 36453519 | Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis. | Haematologica | 2022 |
| 36108424 | Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. | Leuk Res | 2022 |
| 35930750 | Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. | Blood | 2022 |